Diagnocure cancer test deal
This article was originally published in The Gray Sheet
Executive Summary
Firm pays $2.2 million for exclusive rights to two colorectal cancer molecular diagnostics in development by Philadelphia firm Targeted Diagnostics & Therapeutics. The deal, announced May 1, also includes future milestone payments and royalties to TDT for the tests, which are based on detection of the GCC genetic marker. Diagnocure says the deal is the first of what it expects to be several acquisitions in the field. The firm entered an agreement with Gen-Probe in 2003 to develop its PCA3-based test for prostate cancer (1"The Gray Sheet" June 5, 2006, p. 12)...
You may also be interested in...
Gen-Probe’s PCA3 Prostate Cancer Test Could Be Alternative To Biopsy
Gen-Probe will seek approval for its PCA3 urine-based prostate cancer diagnostic as an alternative to the standard regimen of costly, invasive repeat biopsies for men who have abnormal PSA levels but test negative for cancer
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.